注射用伏欣奇拜单抗 | China Drugs ListFirsekibart for Injection | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- 长春金赛药业有限责任公司Changchun GeneScience Pharmaceutical Co., Ltd.
- 药品类型
- 生物药Biologic
- 治疗领域
- 免疫与风湿Immunology & rheumatology
- 公开来源记录的适应症
- 用于成人痛风性关节炎急性发作：非甾体类抗炎药和/或秋水仙碱存在禁忌、不耐受或缺乏疗效，且不适合反复使用类固醇激素。For acute attacks of gouty arthritis in adults for whom nonsteroidal anti-inflammatory drugs and/or colchicine are contraindicated, not tolerated or ineffective, and for whom repeated corticosteroid treatment is inappropriate.
- 适应症来源与口径
- 来源日期： 2025-07. 批准或修订日期为空或为占位值；尚未确认准确修订日期。Source date(s): 2025-07. An approval or revision date is blank or a placeholder; the exact revision date is not confirmed.
- 说明书信息局限
- 已取得完整官方药品说明书。 中国大陆说明书。Complete official prescribing information obtained. Mainland China label.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 2025国家医保目录未匹配；待人工复核Not matched in the 2025 national list; manual review pending
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保核查说明
- 未在提取的目录中匹配到，并不证明被排除。复方制剂仍需人工复核。No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.